Search Results

You are looking at 151 - 160 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach

Clair J. Beard, Shilpa Gupta, Robert J. Motzer, Elizabeth K. O'Donnell, Elizabeth R. Plimack, Kim A. Margolin, Charles J. Ryan, Joel Sheinfeld, and Darren R. Feldman

testicular cancer, updates in care after treatment have become very important. After the diagnosis and treatment of testicular cancer, the goal of follow-up care is to identify relapse early enough that effective salvage therapy can be given. Over time, as

Full access

Highlights of the NCCN Oncology Research Program

overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase II Study of Decitabine and Cedazuridine in Combination With Venetoclax for AML Relapse After Allogenic Hematopoietic Cell Transplantation

Full access

Highlights of the NCCN Oncology Research Program

overseen by the ORP. This feature highlights an NCCN study funded through the grant mechanism. Phase II Study of Decitabine and Cedazuridine in Combination With Venetoclax for AML Relapse After Allogeneic Hematopoietic Cell Transplantation Principal

Full access

CLO23-049: An Unusual Case Presentation of Severe Idiopathic Multicentric Castleman Disease (iMCD)

Himil Mahadevia, Ammar Al-Obaidi, Ujjwal Madan, and Furha Cossor

Objective: To describe a case of severe idiopathic multicentric castleman disease (iMCD) masquerading initially as atypical hemolytic uremic syndrome (aHUS) and showing excellent response to rituximab post relapse on IL-6 antagonist therapy

Full access

Monitoring Minimal Residual Disease in Acute Myeloid Leukemia: Ready for Prime Time?

Farhad Ravandi and Jeffrey L. Jorgensen

monitoring in AML. Outline how pretreatment covariates, such as clinical and molecular predictors, can determine prognosis/survival. Predicting Relapse in AML: Potential for Modification of Therapy Current treatment strategies in acute

Full access

Emerging Treatment Options for B-Cell Lymphomas

Andrew D. Zelenetz

%. The phase II GAUSS study 2 was the first head-to-head study of obinutuzumab versus rituximab in patients with relapsed indolent NHL with a prior response to rituximab. Although a trend toward higher response rates was seen with obinutuzumab, no

Full access

The Role of Hematopoietic Stem Cell Transplant in Follicular Lymphoma

Edward A. Faber Jr. and Julie M. Vose

Initial reports with myeloablative allogeneic HCT show an improvement in relapse/progression compared with autologous HCT, but this improvement is associated with intolerable nonrelapse mortality (NRM). To reduce toxicities associated with high NRM

Full access

After Local Therapy for Esophageal Cancer, Should We Continue to Survey Patients and, If So, Why and How?

Jaffer A. Ajani

surveillance. Whether certain groups of patients benefit from surveillance remains conjectural because of the lack of data. We can make a major distinction in the rates of locoregional relapse among patients who receive trimodality versus bimodality therapies

Full access

Non-Hodgkin’s Lymphomas, Version 3.2012

Andrew D. Zelenetz, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, Naresh Bellam, John C. Byrd, Myron S. Czuczman, Luis Fayad, Martha J. Glenn, Jon P. Gockerman, Leo I. Gordon, Nancy Lee Harris, Richard T. Hoppe, Steven M. Horwitz, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Barbara Pro, Nishitha Reddy, Lubomir Sokol, Lode Swinnen, Christina Tsien, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Maoko Naganuma, and Mary A. Dwyer

randomized trial is comparing outcomes between chemoimmunotherapy with FCR and BR in “fit” patients with previously untreated CLL (CLL10 study). The BR regimen was also active (ORR, 59%; CR, 9%) in patients with relapsed/refractory disease (N= 78) in a

Full access

Multiple Myeloma: New Uses for Available Agents, Excitement for the Future

Kenneth C. Anderson

use current agents, according to recommendations in the 2015 NCCN Guidelines: Panobinostat/bortezomib/dexamethasone as a category 1 option for relapsed myeloma in patients who have received at least 2 prior regimens, including bortezomib and an